Patricia Inácio, PhD, science writer —

Encoded Therapeutics will further develop its lead precision gene therapy platform for Dravet syndrome and other severe genetic disorders after a financing round brought in $104 million from several investors. The company’s goal is to receive approval and market this platform, which aims to overcome key limitations of…

Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational anti-seizure therapy for patients with Dravet syndrome, likely in the third quarter of this year. The U.S. Food and Drug Administration (FDA) refused the first NDA for Fintepla…

  Epygenix Therapeutics has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to assess the safety and efficacy of EPX-100, its investigational therapy for Dravet syndrome. If accepted, Epygenix expects to initiate a Phase 1 trial with healthy volunteers…

Zogenix‘s investigational therapy Fintepla (ZX008) to treat epileptic seizures associated with Dravet syndrome will be marketed in Japan by pharmaceutical company Nippon Shinyaku. Fintepla is a low-dose oral solution of fenfluramine hydrochloride, a compound derived from the stimulant amphetamine. Patients take it with other epileptic treatments…

Epidiolex (cannabidiol) oral solution is now available in the United States as a treatment for seizures in patients age 2 or older who have Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex is developed by GW Pharmaceuticals and will be marketed in the U.S. by its subsidiary, Greenwich Biosciences. The anti-epileptic therapy…

Treatment with stiripentol reduces seizures and can resolve epileptic episodes, retrospective analysis of a small study in Turkish Dravet syndrome children suggests. The study, “Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome,” was published in the Journal of Child Neurology. Stiripentol, sold as Diacomit by…

Fenfluramine, originally developed as an appetite suppressant, shows potential as an anti-epileptic therapy to reduce the seizure rate in Dravet syndrome patients, a review study suggests. The study, “Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome,” was published in…

The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment of focal seizures, which affect only one part of the brain, with or without secondary generalized seizures, in children ages 4 and older. The approval includes Fycompa administered as a…

Supernus Pharmaceuticals now holds the worldwide rights — except in certain markets in Asia — to develop the investigational therapy BIS-001ER, renamed SPN-817, for Dravet syndrome, after a merger agreement to acquire Biscayne Neurotherapeutics, according to a press release. “We are excited to add…

The U.S. Food and Drug Administration (FDA) has approved Biocodex’s Diacomit (stiripentol) as an add-on therapy for seizures associated with Dravet syndrome in patients 2 years and older who are undergoing treatment with Onfi (clobazam), an anticonvulsant therapy marketed by Lundbeck. Diacomit is used as an adjunctive (add-on) therapy for treating …